ABIGAEL DOLLENS: Open Payments
NPI 1023721289 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,567 in 89 payments from 16 companies in 2025. Trend: 2023 $607 · 2024 $772 · 2025 $1,567
Food & beverage: $1,567
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 21 | $325 |
| Lilly USA, LLC | 15 | $224 |
| ABBVIE INC. | 10 | $173 |
| Axsome Therapeutics, Inc. | 5 | $154 |
| Amgen Inc. | 10 | $149 |
| PFIZER INC. | 7 | $140 |
| Supernus Pharmaceuticals, Inc. | 4 | $90 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $59 |
| Corium, LLC | 2 | $53 |
| AstraZeneca Pharmaceuticals LP | 3 | $48 |
Products named: MOUNJARO, Wegovy, Auvelity, Ozempic, PREVNAR 20, OTEZLA, UBRELVY, Qelbree.
Industry payments across TX — which companies pay providers there.
